Company news: Roche

Share this article:
Roche reported disappointing third-quarter sales as key cancer drugs Avastin, Rituxan and Herceptin underperformed. Avastin sales declined 24% in the third quarter, while Herceptin was down 12% and Rituxan sales slid 10%. That, coupled with currency exchange effects, caused the company to miss analyst expectations and trumped an upbeat pipeline report from the firm.
Share this article:

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.